Pfizer is determined to be a magnet for the best science in Quebec and in the Canadian biomedical community



    KIRKLAND, QC, March 28 /CNW Telbec/ - As leading sponsor of the BioMedex
Conference beginning in Laval today, Pfizer will be looking for the best
science to maximize the potential of its research and development activities.
The Pfizer Global Research and Development (PGRD) team will be actively
seeking partnerships with biotechnology firms offering compelling innovative
concepts, proprietary knowledge and unique expertise. The search for research
collaborations beyond its walls and further leveraging third party
collaborations are key priorities for Pfizer. The company's stated strategy is
that one third of its revenues will come from externally sourced compounds.
Pfizer is already a major player in biotherapeutics and plans to greatly
increase the output of candidates in this area.
    During the BioMedex event, Pfizer will be meeting with Quebec and
Canadian biotechnology companies with experimental compounds as well as those
with new drug development science and technologies, including targets and
leads for product discovery, screening technologies, early development
technologies, enabling clinical technologies, diagnostics, formulations and
chemistry.
    "There is no question that biotherapeutics have reached a level of
maturity which will allow the introduction of the next wave of breakthroughs
over the next decade," says Dr. Bernard Prigent, Vice President and Medical
Director, Pfizer Canada. "I think it's an evolution. The direction is set and
it has been a big challenge to translate new knowledge into therapeutics but
we've reached the stage now where there's an acceleration of the translation
of knowledge into actual applications."

    Potential Exciting Development in Quebec?
    -----------------------------------------

    "Innovative ideas and insights developed in the laboratories of the
Quebec and Canadian biotech firms are out there, as well as potential exciting
development candidates and unique or specific technology alliances," adds
Dr. Prigent. "Our team intends to reach out to those fitting with Pfizer's
strategy and eventually apply our resources prudently to turn relevant ideas
into valuable and innovative healthcare solutions. Through the support of this
biopartnering event, Pfizer continues its commitment to lead and foster
innovation in Quebec, in the wake of the alignment of Quebec's health and
economic policies."

    Most Recent Canadian Collaborations
    -----------------------------------

    Worldwide, Pfizer has links with more than 250 partners in academia and
industry to strengthen its position on the cutting edge of science and
biotechnology. Most recent collaborations with Canadian biotech firms include
Montreal-based genetic research firm, Genizon BioSciences (collaboration
agreement for diagnostic rights of this firm's programs in Alzheimer's
disease, attention deficit hyperactivity disorders and endometriosis),
Toronto-based GeneNews (research collaboration for the identification of novel
therapeutic targets and biomarkers for the treatment and diagnosis of
osteoarthritis), and Chromos Molecular Systems Inc.(collaborative program to
genetically engineer production cell lines) based in Burnaby, British
Columbia. In 2006, Pfizer held regional BioPartnering conferences across
Canada to solidify its lead as partner of choice and generate new
collaborative opportunities between biotechnology firms, and Pfizer globally.

    About Pfizer
    ------------

    Pfizer Canada Inc. is the Canadian operation of Pfizer Inc, the world's
leading pharmaceutical company. Pfizer discovers, develops, manufactures and
markets prescription medicines for humans and animals. Pfizer Inc invests more
than US$7 billion annually in R&D to discover and develop innovative
life-saving and life-enhancing medicines in a wide range of Therapeutic Areas,
including Inflammation, Cardiovascular (metabolic and endocrine), Infectious
Diseases, Neuroscience, Oncology, Ophthalmology, Genitourinary, Allergy and
Respiratory. Pfizer Canada is one of the top investors in Canadian R&D,
investing more than $190 million in 2005 alone. The Canadian headquarters of
Pfizer Global Pharmaceuticals is in Kirkland, Quebec. For more information,
visit www.pfizer.ca.




For further information:

For further information: Sylvie Tessier, Pfizer Canada Inc, (514)
693-4609, sylvie.tessier@pfizer.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890